The Global Medical Cannabis Market: From $30.6B in 2025 to $159B by 2033

What does this mean for the global cannabis industry?

The global medical cannabis market is no longer a niche sector. As of 2025, more than 50 countries have enacted legal frameworks permitting some form of medical cannabis access, the UN’s International Narcotics Control Board (INCB) documented 549.2 tonnes of licensed cannabis production globally in 2024, and research firm Market Data Forecast values the global medical cannabis market at $30.6 billion in 2025 — up from $24.9 billion in 2024. That same firm projects the market will reach $159.2 billion by 2033, compounding at 22.9% annually. Competing research firms offer different figures, but the direction of every credible projection is the same: sharply upward.

This growth is not driven by recreational legalization trends, though those matter for the broader cannabis industry. It is driven by something more durable: the convergence of rising patient demand across an expanding set of qualifying conditions, regulatory frameworks maturing in Europe and Asia-Pacific, pharmaceutical-grade supply chains reaching critical scale, and a policy shift in the United States that — after years of stalemate — is now moving toward rescheduling cannabis under federal law. Each of these dynamics reinforces the others.

For investors, operators, and market analysts evaluating the global medical cannabis opportunity, the central challenge is sorting signal from noise. Market projections from different research firms vary significantly — IMARC Group, for example, projects a more conservative $68.6 billion by 2033 at a 7.1% CAGR, while SkyQuest estimates $130.4 billion at 21.7%. This variance reflects genuine methodological differences: some firms model the medical segment exclusively, others capture legal cannabis more broadly; some include CBD wellness products, others restrict to prescription or authorized pharmaceutical preparations. This post presents the range honestly, attributes each figure to its source, and focuses on the structural factors that will determine where within that range the market ultimately lands.

The Numbers: What the Research Firms Say

The most widely cited projection for the global medical cannabis market — $30.6 billion in 2025 growing to $159.2 billion by 2033 at a 22.9% CAGR — comes from Market Data Forecast’s report titled Medical Cannabis Market Size, Trends & Global Forecast. The firm’s baseline data for the current cycle places the 2024 market at $24.9 billion, with 2025 representing the first year of their forecast period.

It is worth noting that Market Data Forecast’s most recent report iteration covers 2026–2034, where the $30.6 billion figure serves as the 2025/base-year anchor and the outer year projection shifts to $195.7 billion by 2034. Investors and analysts citing the "$30.6B to $159.2B by 2033" framing should be aware they are drawing on the 2025–2033 version of this forecast.

Medical Cannabis Market Projections: Research Firm Comparison

Sources: Market Data Forecast, SkyQuest, Emergen Research, Cognitive Market Research, IMARC Group, Grand View Research — figures from firm reports as cited and published. Scope differences account for significant variance between projections.

The honest takeaway from this comparison is that the global medical cannabis market, defined strictly as authorized medical and pharmaceutical use, is most likely valued somewhere in the $21–$37 billion range today and carries a credible path to $100–$160 billion by 2033 if current growth trajectories in Europe, Asia-Pacific, and Latin America continue. The IMARC outlier likely reflects a broader product definition. The Grand View Research figure captures total legal cannabis, not medical specifically.

What matters for investors is not which firm’s number is "right" but which structural drivers will determine the outcome — and those are addressable with verifiable data.

The Regulatory Architecture: Official Sources

Market size projections are only as useful as the policy environment that either enables or constrains them. The global medical cannabis regulatory landscape in 2026 is defined by several concurrent developments that carry official government authority.

United Nations: INCB Narcotic Drugs 2025 Report

The International Narcotics Control Board’s Narcotic Drugs 2025 technical report, released March 9, 2026, provides the only independently verified baseline for global licensed cannabis production. The report documents that global cannabis production for medical and scientific purposes decreased to 549.2 tonnes in 2024, down from prior years. The INCB notes that this apparent decline is at least partly a statistical artifact: new reporting requirements now require countries to distinguish more precisely between cannabis flower, cannabis extracts, and cannabis-related preparations — quantities previously aggregated under "cannabis" are now classified differently, making year-over-year comparisons unreliable as a pure trend signal.

The leading producing countries by volume, according to INCB data (in terms of licensed cultivation and production), include Canada, Australia, and the United Kingdom, while the top exporters by volume are the UK, Canada, and Portugal. Canada alone exported an estimated 240 tonnes of medical cannabis internationally in 2025 — more than double its 2024 export volume of 107 tonnes — with Germany receiving nearly half of those shipments.

The INCB data also documents the persistent tension within the international drug control conventions: member states of the Commission on Narcotic Drugs are increasingly divided on how the 1961 Single Convention applies to non-medical cannabis use, and the December 2020 CND vote that removed cannabis from Schedule IV (but retained it in Schedule I) of the 1961 convention remains consequential for how national medical frameworks interact with international treaty obligations.

United States: Cannabis Rescheduling Moving Forward

The most consequential regulatory development for the global medical cannabis market in 2025–2026 is the United States federal cannabis rescheduling process. On August 29, 2024, the Drug Enforcement Administration published a proposed rulemaking in the Federal Register (Docket No. DEA-1362) proposing to transfer marijuana from Schedule I to Schedule III of the Controlled Substances Act. The proposal received approximately 43,000 public comments.

On April 23, 2026, Acting Attorney General Todd Blanche issued an order that immediately placed FDA-approved products containing marijuana, and products containing marijuana regulated by state medical marijuana licenses, in Schedule III — while initiating an expedited administrative hearing process to begin June 29, 2026 to address the broader rescheduling. This action was preceded by a December 2025 executive order directing the Department of Justice to complete the rescheduling rulemaking and expand federal research on medical marijuana and hemp-derived cannabinoids.

The practical effects of Schedule III placement for FDA-approved and state-licensed medical products include removal of the Section 280E tax burden, expanded banking access, and a more permissive environment for pharmaceutical development and federally funded clinical research. A market of approximately 40 U.S. states with operational medical cannabis programs — estimated by North American regional analysis to represent roughly 75% of the global market by revenue — gaining normalized federal recognition would be the single largest structural catalyst in the global medical cannabis market’s near-term trajectory.

European Union: EUDA and National Frameworks

The European Union Drugs Agency (EUDA) tracks cannabis policy across member states, and the 2025 European Drug Report documents a clear policy divergence: Germany, Malta, Luxembourg, and Czechia have moved on recreational cannabis frameworks, while the medical landscape is governed by national health authority frameworks that vary considerably by country.

Germany is the most significant European medical market by revenue: Prohibition Partners’ Global Medical Cannabis Market Review 2026, published March 2026, estimated Germany’s medical cannabis sales at nearly $1 billion in 2025, representing 155% growth versus 2024, making it the largest medical cannabis market outside North America. The UK reached approximately $298 million in medical cannabis sales in 2025, also doubling year-over-year.

Poland, often overlooked, has emerged as Europe’s largest patient market by registration count — approximately 105,000 registered patients — driven by accessible telemedicine infrastructure. Across Europe, the pattern is consistent: markets where teleclinics have been permitted to prescribe have grown fastest, while markets restricted to in-person specialist referrals have expanded slowly.

WHO Expert Committee Position

The World Health Organization’s Expert Committee on Drug Dependence (ECDD) completed its first-ever formal critical review of cannabis in 2019, recommending removal of cannabis from Schedule IV of the 1961 Single Convention (the most restrictive scheduling category) while retaining Schedule I placement. The Commission on Narcotic Drugs acted on this recommendation in December 2020. The WHO ECDD’s finding that cannabis has demonstrated medical benefits — including for pain, epilepsy, nausea, and multiple sclerosis spasticity — has provided important intergovernmental legitimacy for national medical programs to expand.

Growth Drivers: What Actually Moves the Market

Driver 1: Patient Population Expansion

Global registered medical cannabis patient populations are growing rapidly across every established market:

Sources: Prohibition Partners Global Medical Cannabis Market Review 2026; GrowerIQ market research; Australia TGA; Health Canada medical purpose data (March 2025); INCB

North America accounts for approximately 68% of global medical cannabis revenue, with the U.S. driving the majority of that figure across its 40+ state-level programs. But the growth rate is highest outside North America — Europe, Asia-Pacific, and Latin America are growing from a smaller base but with structural tailwinds (regulatory reform, telemedicine penetration, new-market openings) that make them the critical variable for the 2033 projection.

Driver 2: New-Market Openings

The pace of new medical cannabis program launches has accelerated. A decade ago, fewer than ten countries had operational medical cannabis frameworks. By 2025, that count exceeds 50. Recent significant openings include:

• Germany (2024): The Medical Cannabis Act (MedCanG) deregulated prescriptions, removing the requirement for specialist-only referrals and enabling general practitioners and telemedicine platforms to prescribe. Prescriptions surged 3,300% between March 2024 and December 2025.
• Brazil (2026): ANVISA authorized domestic cultivation for the first time through four interlocking resolutions (RDC 1,012 through 1,015), complementing a patient registry that grew 56% in a single year.
• South Korea: Market projections indicate a growing medical cannabis framework targeting $527 million by 2029.
• New Zealand: Medicinal cannabis supply increased 14x between 2020 and 2025, driven by regulatory simplification under the Medicinal Cannabis Scheme.

Each new-market opening is not merely additive — it validates the model for neighboring jurisdictions and creates export market demand that benefits established producing countries (particularly Canada, Portugal, and the Netherlands).

Driver 3: Expanding Therapeutic Indications

The earliest medical cannabis programs typically restricted access to terminal conditions, intractable epilepsy, or chemotherapy-induced nausea and vomiting. The trajectory in mature markets is toward broader indications:

• Chronic pain is now the dominant indication in Australia, the UK, and Germany, representing the plurality of prescriptions in each market.
• PTSD and anxiety disorders have gained legal recognition as qualifying conditions in Canada, parts of the United States, and Israel.
• Fibromyalgia, lupus, and serious debilitating diseases were added to Brazil’s authorized indications under ANVISA’s RDC 1,015, effective May 2026.
• Multiple sclerosis spasticity has pharmaceutical-grade product approvals (Sativex/nabiximols) in more than 30 countries.

Broader indications mean larger addressable patient populations. As chronic pain — affecting an estimated 1.5 billion people globally — becomes more widely recognized as a qualifying condition, the patient ceiling for medical cannabis rises substantially.

Driver 4: Supply Chain Professionalization

The global medical cannabis supply chain has matured considerably. EU-GMP (Good Manufacturing Practice) certification, originally a Canadian export requirement to reach European markets, has become the de facto global standard. Facilities certified to EU-GMP standards now operate in Canada, Portugal, the Netherlands, Colombia, Australia, Uruguay, and Germany.

This professionalization enables cross-border trade at pharmaceutical quality levels — a prerequisite for market expansion beyond North America. Canada exported 240 tonnes (Prohibition Partners reported 275,343 kg for 2025) of medical cannabis in 2025, more than doubling 2024 volumes, with Germany absorbing roughly half of that volume. Portugal has evolved into Europe’s primary processing hub, re-exporting to Germany, UK, Poland, and other EU markets.

Regional Market Snapshot: Where the Growth Is

North America: The Mature Foundation

North America remains the largest single region, accounting for an estimated 68%+ of global medical cannabis revenue. The U.S., despite operating without a federally legal framework for most of the market’s growth period, generated the majority of this revenue across state-licensed medical programs. The pending Schedule III reclassification would formalize and expand this market — reducing compliance friction, enabling pharmaceutical research, and unlocking banking and tax structures that have constrained operators.

Canada’s domestic medical market has stabilized at approximately 161,000 medical-only registered clients (March 2025 data, Health Canada) — a significant decline from a peak near 370,000 in 2019, largely because recreational legalization in 2018 reduced the practical incentive for medical-only registration. Canada’s contribution to the global market is now increasingly as an exporter rather than as a domestic patient market.

Europe: The Fastest-Growing Region

Europe is the highest-growth region in the global medical cannabis market, driven by Germany’s deregulation, the UK’s telemedicine expansion, Poland’s patient growth, and Portugal’s emergence as an EU-GMP processing hub. The combined Germany and UK markets doubled in 2025 according to Prohibition Partners’ data. France, Spain, Italy, and the Netherlands have active or developing medical frameworks that are not yet at scale.

The EU-GMP standard is simultaneously Europe’s biggest compliance cost and its biggest competitive moat: operators who achieve certification can access all EU member state markets; those who cannot are locked out entirely. This dynamic is accelerating consolidation around a small number of large, certified producers and processors.

Asia-Pacific: Emerging Scale

Australia’s medical cannabis market is approaching AUD $1 billion in annual revenue (2025), with 700,000–900,000 active patients, 41 licensed cultivators, and a TGA regulatory framework that has streamlined Special Access Scheme approvals. New Zealand, Thailand (which legalized medical cannabis in 2020), South Korea, and Japan (where medical CBD was authorized under specific conditions) represent additional patient pools opening up.

Asia-Pacific’s combined market remains smaller than Germany by revenue, but population scale — and the demographic profile of aging populations with high chronic disease burdens in Japan, South Korea, and Australia — makes it a significant long-term variable in the 2033 projection.

Latin America: Infrastructure Investment

Brazil’s 873,000-patient registry, combined with newly authorized domestic cultivation, makes it the dominant Latin American medical cannabis market. Colombia, Uruguay, Peru, and Ecuador operate smaller programs. The region’s contribution to the global market is currently modest by revenue but significant as a production base — Colombia and Ecuador offer low-cost cultivation environments that could reshape global supply chain economics in the 2027–2030 period.

What Operators and Investors Need to Know

The variance between research firm projections — $68.6 billion versus $159.2 billion versus $216 billion by 2033 — is not a failure of market intelligence. It reflects genuine uncertainty about how quickly three variables will evolve: (1) how many additional countries will open medical cannabis programs, (2) how broadly indications will expand in existing markets, and (3) how quickly average revenue per patient will grow or compress as competition intensifies.

What is not uncertain is the direction. Every credible projection points to sustained double-digit growth in licensed medical cannabis through 2033, driven by patient demand that is growing faster than any single regulatory framework can constrain and by a global supply chain that is professionalizing at pharmaceutical-grade standards.

For operators evaluating which markets to enter, the analytical framework is straightforward: markets where telemedicine is permitted for cannabis prescriptions (Australia, UK, Germany, Poland, Brazil) have grown fastest and are likely to continue outperforming. Markets restricted to specialist-only in-person access (France, Italy, Spain, most of the United States before Schedule III) represent the upside case if regulatory liberalization occurs.

For compliance infrastructure specifically, the key implication is that the same EU-GMP, seed-to-sale traceability, and batch-level quality assurance requirements that defined Canadian and European compliance in 2020–2024 are becoming the global standard. Operators entering Brazil, Australia, South Korea, or New Zealand are increasingly encountering the same compliance architecture — GMP certification, chain of custody documentation, laboratory testing per batch, and digital record-keeping — that mature market operators have been building for years. Understanding how that infrastructure compares across Canada’s 2025 Health Canada regulatory amendments and Australia’s TGA framework is essential for any cross-border operator.

The global medical cannabis market is not a single market — it is a collection of national markets connected by trade flows, professional standards, and investor capital. The $30.6 billion figure for 2025 represents what those 50+ national markets generate today. The path to $159 billion by 2033 requires those national markets to continue expanding their patient bases, broadening their indications, and normalizing their regulatory frameworks. The evidence from established markets — Germany’s 155% growth in a single year, Australia’s path to AUD $1 billion, Brazil’s 56% annual patient growth — suggests that trajectory is achievable.

What determines whether the outcome is closer to the IMARC estimate of $68 billion or the Market Data Forecast estimate of $159 billion is largely a question of regulatory will and supply chain execution. On both dimensions, the 2025–2026 period is delivering positive signals.

How GrowerIQ Operates at the Intersection

The global medical cannabis market’s growth creates a specific operational challenge that every operator — whether cultivating in Canada, processing in Portugal, or building a patient-facing program in Germany — shares: compliance documentation that meets the evidentiary standards of multiple regulatory regimes simultaneously. EU-GMP, Health Canada’s Cannabis Regulations, ANVISA’s RDC 1,013, the TGA’s TGO 93, and the relevant DEA/state frameworks in the U.S. all demand traceability, batch testing, and chain-of-custody documentation at pharmaceutical-grade standards.

GrowerIQ’s seed-to-sale compliance platform was purpose-built for this environment. The platform operates in more than 24 countries across seven languages, supporting licensed producers, processors, and medical cannabis operators from Health Canada LP environments to the EU-GMP certified facilities driving Canada’s 240-tonne export surge to Germany and beyond, and the emerging cultivation markets where compliance infrastructure determines who receives — and retains — their operating license.

As the global medical cannabis market expands toward its 2033 projection, the operators who build compliant, auditable, digitally traceable operations today will be positioned to follow the market wherever it grows next. Those who do not will face the same barrier to entry in every new jurisdiction they attempt to enter: the compliance gap between what they have built and what regulators require.

The market is large enough to absorb many players. The compliance standards are specific enough to separate those who are operationally ready from those who are not.

For a detailed view of how these global dynamics play out in one of the market’s fastest-growing regions, see GrowerIQ’s analysis of Australia’s billion-dollar cannabis milestone — a market that moved from regulatory framework to AUD $1 billion in revenue in under a decade, driven by exactly the patient-access and supply-chain dynamics shaping the global picture.

This analysis is current as of May 2026 and draws on the UN International Narcotics Control Board Narcotic Drugs 2025 Technical Report (incb.org, released March 9, 2026), U.S. Department of Justice official press releases on cannabis rescheduling, Health Canada medical cannabis purpose data (canada.ca), and the WHO Expert Committee on Drug Dependence recommendations (who.int), alongside market sizing data from Market Data Forecast, Prohibition Partners, SkyQuest, Emergen Research, and IMARC Group. Figures reflect the best available data as of the publication date.

Sources

• Market Data Forecast — Medical Cannabis Market Size, Trends & Global Forecast — Market Data Forecast
• INCB Narcotic Drugs 2025 Report: Press Release — International Narcotics Control Board (UN Agency)
• INCB Narcotic Drugs 2025 eBook — Full Technical Report — International Narcotics Control Board (UN Agency)
• INCB Cannabis Production Estimates 2025 — Country-Level Data — International Narcotics Control Board (UN Agency)
• U.S. Department of Justice — Schedule III Placement of FDA-Approved and State-Licensed Cannabis Products (April 23, 2026) — U.S. Department of Justice
• DEA Federal Register Proposed Rulemaking — Rescheduling of Marijuana (August 29, 2024) — U.S. Drug Enforcement Administration / Federal Register
• WHO Expert Committee on Drug Dependence — Review of Cannabis — World Health Organization
• EUDA — Cannabis: Health and Social Responses — European Union Drugs Agency
• EUDA — European Drug Report 2025 — European Union Drugs Agency
• Health Canada — Data on Cannabis for Medical Purposes — Health Canada (Government of Canada)
• Prohibition Partners — Global Medical Cannabis Market Review 2026 — Prohibition Partners
• Business of Cannabis — UK and Germany Medical Cannabis Markets Both Double in 2025 — Business of Cannabis / Prohibition Partners data
• SkyQuest — Medical Cannabis Market Size, Share, and Growth Analysis — SkyQuest Technology
• Emergen Research — Medical Cannabis Market Size (2024–2033) — Emergen Research
• IMARC Group — Global Medical Cannabis Market Size 2033 — IMARC Group
• Grand View Research — Legal Cannabis Market Size & Share — Grand View Research
• GrowerIQ — Canada Exports 240 Tonnes of Cannabis in 2025
• GrowerIQ — Australia’s Billion-Dollar Cannabis Milestone
• GrowerIQ — Health Canada Cannabis Regulations 2025